Nicolas Coudurier – CEO, Biocodex
Biocodex has evolved from a pioneering French laboratory built around a single yeast strain into an international healthcare group spanning microbiota, women’s health and a focused orphan-disease activity. In this…
Address: rue des Trois Arbres 16, 1180 Brussels, Belgium
Tel: +32 (0)2 370 47 90
Biocodex is an independent, family-owned French pharmaceutical company founded in 1953 by Michel Hublot and François Vallet.
Our mission is to develop and make accessible to doctors and their patients, effective and safe products which improve the health and quality of life of patients.
> Our pledge: to always be at the service of the patient.
> Our commitment: to develop specific and original products.
> Our priority: to target our products on the best therapeutic indications, with the greatest tolerance/efficiency benefit.
> Our outlook: to always work toward the long term.
Biocodex is specialised in:
Gastroenterology,
Neurology & Psychiatry,
Pain Treatment,
Treatment of degenerative osteoarthritis.
Biocodex has evolved from a pioneering French laboratory built around a single yeast strain into an international healthcare group spanning microbiota, women’s health and a focused orphan-disease activity. In this…
Biocodex’s new general manager gives an overview of the affiliates ‘new deal’ program, and how the company has adjusted its approach to better fit the contemporary Turkish environment. What attracted…
Although Biocodex has a commercial presence in over 100 countries, it currently operates only five subsidiaries, one of them being Biocodex Belgium. What were primary motivating factors behind this strategic…
You have been at your current position for less than a year, and joined BIOCODEX after having managed the Russian affiliate of Yves Saint Laurent. You have a long history…
Representatives of Belgian associations for innovative pharma, generics and biosimilars, medtech, OTC, biotech, hospitals, and medical professionals share their key agenda priorities. These include where they feel that change is…
Germany and Belgium have long held an important trading relationship, says Margit Kunz of AHK Debelux, the German chamber of commerce in Belgium and Luxembourg. She outlines some of the…
Perhaps to the surprise of many, Belgium is the world’s second-largest producer of vaccines, behind only the US, and – capitalising on its years of experience in the field –…
Back home in Belgium after a stellar stint in Big Pharma, Dr Paul Stoffels is now looking to reshape the future of cancer care with the previously struggling biotech he…
Belgian healthcare performs strongly across most metrics and international comparisons, but – as elsewhere – there remains room for improvement in terms of integrating patient feedback and experience into the…
20-year Astellas veteran Mark Dekker – now back in his home country of the Netherlands and overseeing the Benelux cluster having primarily developed his career in emerging European markets –…
Marnix Denys of beMedTech – the Belgian association for the medical technology industry – outlines the agenda priorities for the organisation that he hopes will lead to a more value-driven…
RaDiOrg aims to support rare disease patients and patient organisations in Belgium, defend their interests, and raise awareness of what can be devastating and little-understood conditions. Director Eva Schoeters –…
The newly merged Port of Antwerp-Bruges is the world’s first GDP-compliant seaport. CCO Tom Hautekiet explains the significant role the Port is playing in global healthcare supply chains – leveraging…
Back home in Belgium after a stellar stint in Big Pharma, Dr Paul Stoffels* is now looking to reshape the future of cancer care with the biotech he helped co-found…
Univercells is a group of companies founded a decade ago based around the concept of revolutionizing the availability of biologics around the world through making essential medicines affordable to all,…
GSK has undergone a number of changes in recent years. After driving a major transformation that began in 2017 to strengthen its R&D performance, the British multinational suffered the impact…
See our Cookie Privacy Policy Here
